(pancrelipase) Delayed-Release Capsules, USP
CREON® 5 Capsules are orally administered and contain pancrelipase (lipase 5,000 USP Units, protease 18,750 USP Units and amylase 16,600 USP Units per capsule) which is of porcine pancreatic origin. Each CREON 5 (pancrelipase delayed-release minimicrospheres) Capsule is filled with 124 mg of delayed-release MINIMICROSPHERES®.
Inactive ingredients include dibutyl phthalate, dimethicone, hydroxypropylmethylcellulose phthalate, light mineral oil and polyethylene glycol. The capsule shells contain gelatin, red iron oxide, titanium dioxide, yellow iron oxide and FD & C blue No. 2. The capsule imprinting ink contains dimethicone, 2-ethoxyethanol, shellac, soya lecithin, and titanium dioxide.
What are the possible side effects of pancrelipase?
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have severe or unusual stomach pain. This could be a symptom of a rare but serious bowel disorder.
Less serious side effects may include:
- nausea or vomiting;
- mild stomach pain or upset;
- diarrhea or constipation;
- bloating or gas;
- greasy stools;
- rectal irritation;
- headache, dizziness;
- cough; or
CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules are indicated for patients with pancreatic exocrine insufficiency as is often associated with:
- cystic fibrosis
- chronic pancreatitis
- post-gastrointestinal bypass surgery (e.g., Billroth II gastroenterostomy)
- ductal obstruction from neoplasm (e.g., of the pancreas or common bile duct)
DOSAGE AND ADMINISTRATION
Clinical experience should dictate initial starting dose. Doses should be taken during meals or snacks, not before or after. Do not take without food.
Adults and Children Over 6 Years Old
Usual initial starting dosage is two to four CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules per meal or snack.
Children Under 6 Years Old
The exact dosage of CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules should be selected based on clinical experience for this age group. Patients can be started on one to two capsules per meal or snack.
For cystic fibrosis patients, typical doses are 1,500 - 3,000 USP lipase units/kg/meal. Dosage should be adjusted according to the severity of the disease, control of steatorrhea and maintenance of good nutritional status. Doses in excess of 6,000 USP lipase units/kg/meal are not recommended.
Dose increases, if required, should occur with careful monitoring of body weight and stool fat content. When changing strengths of pancreatic enzyme products, care should be taken to maintain equivalent lipase units for each divided dosage.
It is important to ensure adequate hydration of patients at all times while taking pancreatic enzymes.
Where swallowing of capsules is difficult, the capsules may be carefully opened and the MINIMICROSPHERES added to a small amount of soft food, with a pH less than 5.5. The soft food should be swallowed immediately without chewing and followed with a glass of water or juice to insure swallowing.
CREON 5 MINIMICROSPHERES (Pancrelipase Delayed-release Capsules, USP) are available in a two-piece gelatin capsule (orange opaque top half, blue opaque bottom half) imprinted in white with "SOLVAY" and "1205". Each capsule contains tan-colored delayed-release MINIMICROSPHERES of pancrelipase supplied in bottles of:
CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules must be stored at 25ºC (77ºF); excursions permitted to 15°-30°C (59°- 86°F). [See USP Controlled Room Temperature.] PROTECT FROM MOISTURE. DO NOT REFRIGERATE. Dispense in tight, light-resistant containers. For human consumption only.
Manufactured By: Solvay Pharmaceuticals GmbH, Hannover, Germany. Marketed by: Solvay Pharmaceuticals, Inc. Marietta, GA 30062. Rev Feb 2006. FDA Rev date: n/a
The most frequently reported adverse reactions to pancreatic enzyme-containing products are gastrointestinal in nature which may include nausea, vomiting, bloating, cramping, constipation or diarrhea. Less frequently, allergic-type reactions have also been observed. Very high doses of pancreatin have been associated with hyperuricosuria and hyperuricemia.
No information provided.
Should symptoms of hypersensitivity appear, discontinue medication and initiate symptomatic and supportive therapy if necessary.
Strictures in the ileo-cecal region and/or ascending colon have been reported in cystic fibrosis patients treated with high doses of high-potency pancreatic enzyme supplements containing 20,000 or greater USP units of lipase per capsule. The underlying mechanism is unknown, but caution should be exercised when doses in excess of 6,000 USP units lipase per kg per meal fail to resolve symptoms, especially in patients with a history of intestinal complications such as meconium ileus equivalent, short bowel syndrome, surgery or Crohn's disease. If symptoms suggestive of gastrointestinal obstruction occur, the possibility of bowel stricture should be investigated including evaluation of pancreatic enzyme therapy.
CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules MINIMICROSPHERES SHOULD NOT BE CRUSHED OR CHEWED or placed on foods having a pH greater than 5.5. These can dissolve the protective enteric coating resulting in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies in animals have not been performed to evaluate carcinogenic potential.
Pregnancy, Category C
Animal reproduction studies have not been conducted with pancrelipase. It is also not known whether pancrelipase can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules should be given to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules are administered to a nursing mother.
No information provided.
CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules are contraindicated in the early stages of acute pancreatitis or in patients who are known to be hypersensitive to pork protein.
The pancreatic enzymes in CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules are enteric-coated to resist gastric destruction or inactivation. The pancreatic enzymes catalyze the hydrolysis of fats to glycerol and fatty acids, protein into proteoses and derived substances and starch into dextrins and short chain sugars.
CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules are a pancreatic enzyme product prescribed to promote improved digestion of foods, especially fat. The prescribed dosage should be taken with each meal and snack or as directed by the physician. The capsules can be swallowed whole, or the contents poured on soft, bland food. Care should be taken to avoid chewing or crushing of the capsule contents, which can result in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity. Patients should maintain adequate fluid intake. The prescribed dose range should not be exceeded without calling your doctor.
The most common adverse reactions involve the stomach and intestine including diarrhea, nausea, vomiting, bloating, constipation, stomach cramps or pain. If these symptoms are persistent, contact your doctor.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.